Physician profile
Jason Spring
NPI 1114011459
$1,032.81
in general payments reported to CMS, 2019-2025
16 companies · $827 in 2025
The $827 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $15.07 · 2024: $191 · 2025: $827.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,033.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,032.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $436.70 | 2024-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $136.62 | 2024-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $78.81 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $64.63 | 2025 | |
| Abbvie INC. | $49.46 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $45.27 | 2025 | Airsupra |
| Sumitomo Pharma America, INC. | $44.05 | 2024-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $40.34 | 2024-2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.52 | 2025 | Jardiance |
| Pfizer INC. | $21.12 | 2024 | |
| Astellas Pharma US INC | $18.41 | 2025 | Veozah |
| Esperion Therapeutics, INC. | $18.18 | 2024 | Nexletol |
| Takeda Pharmaceuticals U.S.A., INC. | $16.56 | 2024 | Trintellix |
| Lilly USA, LLC | $15.07 | 2023 | Mounjaro, Trulicity |
| Aimmune Therapeutics, INC. | $14.44 | 2025 | Zenpep |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $5.63 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Spring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.